Trial Profile

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Interferon alpha-2b; Interferon alpha-2b
Indications Malignant melanoma
Focus Therapeutic Use

Most Recent Events

11 Apr 2025 Planned End Date changed from 7 Mar 2025 to 19 Mar 2026.
03 Apr 2024 Planned End Date changed from 26 Jun 2035 to 7 Mar 2025.
06 Jun 2023 Results assessing a Lasso Cox score consisting of CTLA4+ regulatory T cells, monocytic myeloid derived suppressor cells, and CXCR3+ CD8+ T cells, presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com